Why Daiichi Sankyo is betting early on SylamoreBio’s SyLEC delivery platform for CNS programs
SylamoreBio partners with Daiichi Sankyo to test SyLEC CNS delivery technology. Find out what this collaboration changes for brain drug development.
Is DOXA the multi-mechanism small molecule NewcelX needs for narcolepsy and ALS?
NewcelX Ltd. has announced the publication of its international DOXA compound patent in China, further securing intellectual property protection for its cross-domain pipeline in neurology and metabolic diseases. The patent application covers a new class of small molecules derived from quinazoline, benzothiazine, and benzoxazine scaffolds. These compounds are designed to modulate orexin signaling, neuroinflammation, and […]